- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Optimizing BTKi Treatment Strategies
The panelists provide perspectives on critical aspects of the CLL and SLL treatment landscape.
EP: 1.Clinical Characteristics Distinguishing CLL and SLL
EP: 2.Quality of Life Impacted By CLL and SLL Diagnosis and Management
EP: 3.Evaluating Current Treatment Landscape of CLL and SLL
EP: 4.Unmet Needs In CLL and SLL Treatment Management
EP: 5.Indications and Considerations For BTK Inhibitor Use In CLL and SLL Management
EP: 6.Examining Safety and Efficacy of BTK Inhibitors In CLL and SLL Treatment
EP: 7.Determining Optimal CLL / SLL Therapy: Ibrutinib, Acalabrutinib and Zanubrutinib
EP: 8.Key Highlights From ASH 2023
EP: 9.Economic Burden Associated With BTK Inhibitor Use
EP: 10.Patient Education Driving BTK Inhibitor Treatment Adherence
EP: 11.Optimizing BTKi Treatment Strategies
EP: 12.Key Considerations for Treating Patients Diagnosed With CLL and SLL
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; Jennifer Woyach, MD.
The group discusses anticipated advancements in Bruton tyrosine kinase inhibitor (BTKi) therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). A key goal is converting continuous BTKi treatment into time-limited approaches through combinations or stopping criteria based on deep responses. This could improve quality of life and reduce financial burdens compared with indefinite therapy.Incorporating assessment of minimal residual disease as a trigger for discontinuation is an exciting strategy being explored in trials.
The panelists highlight the potential of leveraging precision medicine through mutational profiling and cytogenetics to guide upfront BTKi selection and sequencing. This allows customization based on a patient’s molecular features rather than a one-size-fits-all approach. Expanding the options for noncovalent BTKis that can overcome specific resistance mutations will enable optimal treatment sequencing tailored to a patient’s mutational profile when disease relapse occurs.
Overall, the group is optimistic about integrating predictive biomarkers, combination strategies, and novel targeted agents to usher in an era of personalized BTKi therapy in CLL and SLL. This offers hope for maximizing treatment outcomes while minimizing toxicity burdens for patients.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
